ACE-031
MODERATE EVIDENCEAlso known as: ActRIIB-Fc, Activin receptor fusion protein
Investigational — clinical development discontinued
Educational Overview
A soluble activin receptor fusion protein studied as a myostatin pathway inhibitor. Clinical development was discontinued after adverse findings in trials.
Research Mechanism
Acts as a decoy receptor binding myostatin and related ligands, studied for effects on muscle mass in trial settings.
Areas of Study
- Myostatin pathway research
- Muscle biology (clinical trials, discontinued)
Safety Considerations
Clinical development was halted following reports of adverse vascular events including epistaxis and telangiectasia in trial participants. Human use is not supported. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
How do I get pricing?
Request a quote and our team will respond with current pricing and available sizes for your account.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.